TENX
TENAX THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.52
+11.76%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.41
From 52W high−91.70%
Volume2.57M
Market cap$56.88M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.41
From 52W high
−91.70%
Volume
2.57M
Market cap
$56.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
29.6
MomentumView details →
1D Return
+11.76%
YTD Return
−87.65%
SummaryUpdated Jun 1, 2026
Tenax Therapeutics, Inc. (NASDAQ:TENX) is a specialty pharmaceutical company founded in 1967 and headquartered in Morrisville, North Carolina. Originally known as Oxygen Biotherapeutics, Inc., the company rebranded to Tenax Therapeutics in September 2014 to reflect its focus on developing treatments for cardiovascular and pulmonary diseases. The company has been publicly traded since 1994 and operates as a clinical-stage biopharmaceutical company with no current revenue-generating products, focusing entirely on drug development and clinical trials.
Similar companies
Latest newsMore news →
Tenax Therapeutics shares rose 3.8% in premarket trading after presenting additional data from its Phase 3 LEVEL trial of TNX-103 at the European Society of Cardiology Congress in Munich.49d agoADAR1 Capital Management, a 10% owner and director of Tenax Therapeutics, acquired 1,025,867 common shares totaling approximately $1.81 million over several days from August 20 to August 24, 2026.56d agoTenax Therapeutics announced topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF, which did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo.70d ago